Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression

Brain, Behavior, and Immunity

Volumn 48, Issue , 2015, Pages 8-18

  Nikkheslat, Naghmeh ^a,b   Zunszain, Patricia A ^a   Horowitz, Mark A ^a   Barbosa, Izabela G ^a   Parker, Jennie A ^b   Myint, Aye Mu ^d   Schwarz, Markus J ^d   Tylee, Andre T ^a   Carvalho, Livia A ^c   Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROEHAMPTON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiovascular risk factors; Corticosteroid receptor; Cytokine; Kynurenine; Major depressive disorders; Neuroendocrine; Stress

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INTERLEUKIN 6; KYNURENINE; TRYPTOPHAN; VASCULOTROPIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANALYTICAL PARAMETERS; ARTICLE; BECK DEPRESSION INVENTORY; BIOAVAILABILITY; CLINICAL INTERVIEW SCHEDULE REVISED; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DEPRESSION ASSESSMENT; ELISA KIT; FEMALE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; HYPOACTIVITY; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IN VITRO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; KYNURENINE PATHWAY; KYNURENINE TRYPTOPHAN RATIO; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SALIVA LEVEL; SIGNAL TRANSDUCTION; UNITED KINGDOM; AGE; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SEX DIFFERENCE;

AGE FACTORS; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DEPRESSIVE DISORDER; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GLUCOCORTICOID; SEX FACTORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939169408     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.02.002     Document Type: Article

References (116)

1. Anacker, C., Zunszain, P.A., Cattaneo, A., Carvalho, L.A., Garabedian, M.J., Thuret, S., Price, J., Pariante, C.M., 2011. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol. Psychiatry 16, 738-750.
2. Barton, B.E., 1996. The biological effects of interleukin 6. Med. Res. Rev. 16, 87-109.
3. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571.
4. Beck, A.T., Steer, R.A., Carbin, M.G., 1988. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin. Psychol. Rev. 8, 77-100.
5. Beekman, A.T., Geerlings, S.W., Deeg, D.J., Smit, J.H., Schoevers, R.S., de Beurs, E., Braam, A.W., Penninx, B.W., van Tilburg, W., 2002. The natural history of latelife depression: a 6-year prospective study in the community. Arch. Gen. Psychiatry 59, 605-611.
6. Berent, D., Macander, M., Szemraj, J., Orzechowska, A., Galecki, P., 2014. Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins. Acta Neurobiol. Exp. (Wars) 74, 82-90.
7. Bhattacharyya, M.R., Molloy, G.J., Steptoe, A., 2008. Depression is associated with flatter cortisol rhythms in patients with coronary artery disease. J. Psychosom. Res. 65, 107-113.
8. Blann, A.D., Belgore, F.M., McCollum, C.N., Silverman, S., Lip, P.L., Lip, G.Y., 2002. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin. Sci. (Lond.) 102, 187-194.
9. Blazer 2nd, D.G., 2000. Controversies in community-based psychiatric epidemiology: let the data speak for themselves. Arch. Gen. Psychiatry 57, 227-228.
10. Bruce, M.L., 2002. Psychosocial risk factors for depressive disorders in late life. Biol. Psychiatry 52, 175-184.
11. Byrne, A.M., Bouchier-Hayes, D.J., Harmey, J.H., 2005. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. 9, 777-794.
12. Carney, R.M., Freedland, K.E., 2003. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol. Psychiatry 54, 241-247.
13. Carney, R.M., Rich, M.W., Tevelde, A., Saini, J., Clark, K., Freedland, K.E., 1988. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J. Psychosom. Res. 32, 159-164.
14. Carney, R.M., Freedland, K.E., Rich, M.W., Smith, L.J., Jaffe, A.S., 1993. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am. J. Med. 95, 23-28.
15. Carvalho, L.A., Juruena, M.F., Papadopoulos, A.S., Poon, L., Kerwin, R., Cleare, A.J., Pariante, C.M., 2008. Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression. Neuropsychopharmacology 33, 3182-3189.
16. Carvalho, L.A., Garner, B.A., Dew, T., Fazakerley, H., Pariante, C.M., 2010. Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. Eur. Neuropsychopharmacol. 20, 379-387.
17. Carvalho, L.A., Urbanova, L., Hamer, M., Hackett, R.A., Lazzarino, A.I., Steptoe, A., 2015. Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology 51, 209-218.
18. Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., Craig, I.W., Anacker, C., Zunsztain, P.A., McGuffin, P., Pariante, C.M., 2013. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38, 377-385.
19. Chrousos, G.P., Gold, P.W., 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267, 1244-1252.
20. Clark-Raymond, A., Halaris, A., 2013. VEGF and depression: a comprehensive assessment of clinical data. J. Psychiatr. Res. 47, 1080-1087.
21. Cohen, S., Janicki-Deverts, D., Doyle, W.J., Miller, G.E., Frank, E., Rabin, B.S., Turner, R.B., 2012. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc. Natl. Acad. Sci. 109, 5995-5999.
22. Crofford, L.J., Pillemer, S.R., Kalogeras, K.T., Cash, J.M., Michelson, D., Kling, M.A., Sternberg, E.M., Gold, P.W., Chrousos, G.P., Wilder, R.L., 1994. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 37, 1583-1592.
23. Dantzer, R., O'Connor, J.C., Lawson, M.A., Kelley, K.W., 2011. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36, 426-436.
24. Davidson, K.W., 2012. Depression and coronary heart disease. ISRN Cardiol. 2012, 743813.
25. Demitrack, M.A., Crofford, L.J., 1998. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann. N. Y. Acad. Sci. 840, 684-697.
26. Dome, P., Teleki, Z., Rihmer, Z., Peter, L., Dobos, J., Kenessey, I., Tovari, J., Timar, J., Paku, S., Kovacs, G., Dome, B., 2009. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol. Psychiatry 14, 523-531.
27. Dyer, A.R., Persky, V., Stamler, J., Paul, O., Shekelle, R.B., Berkson, D.M., Lepper, M., Schoenberger, J.A., Lindberg, H.A., 1980. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am. J. Epidemiol. 112, 736-749.
28. Elovainio, M., Hurme, M., Jokela, M., Pulkki-Raback, L., Kivimaki, M., Hintsanen, M., Hintsa, T., Lehtimaki, T., Viikari, J., Raitakari, O.T., Keltikangas-Jarvinen, L., 2011. Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study. J. Affect. Disord. 133, 611-614.
29. Empana, J.P., Sykes, D.H., Luc, G., Juhan-Vague, I., Arveiler, D., Ferrieres, J., Amouyel, P., Bingham, A., Montaye, M., Ruidavets, J.B., Haas, B., Evans, A., Jouven, X., Ducimetiere, P., 2005. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 111, 2299-2305.
30. Ershler, W.B., Keller, E.T., 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51, 245-270.
31. Ferrucci, L., Harris, T.B., Guralnik, J.M., Tracy, R.P., Corti, M.C., Cohen, H.J., Penninx, B., Pahor, M., Wallace, R., Havlik, R.J., 1999. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc. 47, 639-646.
32. Fleisch, M., Billinger, M., Eberli, F.R., Garachemani, A.R., Meier, B., Seiler, C., 1999. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 100, 1945-1950.
33. Fries, E., Hesse, J., Hellhammer, J., Hellhammer, D.H., 2005. A new view on hypocortisolism. Psychoneuroendocrinology 30, 1010-1016.
34. Gold, P.W., Chrousos, G.P., 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7, 254-275.
35. Halaris, A., 2013. Inflammation, heart disease, and depression. Curr. Psychiatry Rep. 15, 400.
36. Hansson, G.K., 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695.
37. Harris, T.B., Ferrucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger Jr., W.H., Heimovitz, H., Cohen, H.J., Wallace, R., 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106, 506-512.
38. Hellhammer, J., Schlotz, W., Stone, A.A., Pirke, K.M., Hellhammer, D., 2004. Allostatic load, perceived stress, and health: a prospective study in two age groups. Ann. N. Y. Acad. Sci. 1032, 8-13.
39. Herve, C., Beyne, P., Jamault, H., Delacoux, E., 1996. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. B Biomed. Appl. 675, 157-161.
40. Hsuchou, H., Kastin, A.J., Mishra, P.K., Pan, W., 2012. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell. Physiol. Biochem. 30, 1109-1119.
41. Iga, J., Ueno, S., Yamauchi, K., Numata, S., Tayoshi-Shibuya, S., Kinouchi, S., Nakataki, M., Song, H., Hokoishi, K., Tanabe, H., Sano, A., Ohmori, T., 2007. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 658-663.
42. Ikeda, U., Ito, T., Shimada, K., 2001. Interleukin-6 and acute coronary syndrome. Clin. Cardiol. 24, 701-704.
43. Irwin, M.R., Miller, A.H., 2007. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21, 374-383.
44. Isung, J., Mobarrez, F., Nordstrom, P., Asberg, M., Jokinen, J., 2012. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J. Biol. Psychiatry 13, 468-473.
45. Jiang, W., Krishnan, R.R., O'Connor, C.M., 2002. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 16, 111-127.
46. Jin, K., Zhu, Y., Sun, Y., Mao, X.O., Xie, L., Greenberg, D.A., 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. USA 99, 11946-11950.
47. Kahl, K.G., Bens, S., Ziegler, K., Rudolf, S., Kordon, A., Dibbelt, L., Schweiger, U., 2009. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34, 353-357.
48. Katsuura, S., Kamezaki, Y., Yamagishi, N., Kuwano, Y., Nishida, K., Masuda, K., Tanahashi, T., Kawai, T., Arisawa, K., Rokutan, K., 2011. Circulating vascular endothelial growth factor is independently and negatively associated with trait anxiety and depressive mood in healthy Japanese university students. Int. J. Psychophysiol. 81, 38-43.
49. Keck, P.J., Hauser, S.D., Krivi, G., Sanzo, K., Warren, T., Feder, J., Connolly, D.T., 1989. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312.
50. Knijff, E.M., Nadine Breunis, M., Kupka, R.W., De wit, H.J., Ruwhof, C., Akkerhuis, G.W., Nolen, W.A., Drexhage, H.A., 2007. An imbalance in the production of IL-1ß and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 9, 743-753.
51. Kohn, R., Epstein-Lubow, G., 2006. Course and outcomes of depression in the elderly. Curr. Psychiatry Rep. 8, 34-40.
52. Kop, W.J., Gottdiener, J.S., 2005. The role of immune system parameters in the relationship between depression and coronary artery disease. Psychosom. Med. 67 (Suppl. 1), S37-S41.
53. Kotan, Z., Sarandol, E., Kirhan, E., Ozkaya, G., Kirli, S., 2012. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther. Adv. Psychopharmacol. 2, 65-74.
54. Lapin, I.P., Oxenkrug, G.F., 1969. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1, 132-136.
55. Lee, B.H., Kim, Y.K., 2012. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J. Affect. Disord. 136, 181-184.
56. Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol. Med. 22, 465-486.
57. Libby, P., 2006. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 83, 456S-460S.
58. Licht, T., Goshen, I., Avital, A., Kreisel, T., Zubedat, S., Eavri, R., Segal, M., Yirmiya, R., Keshet, E., 2011. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl. Acad. Sci. 108, 5081-5086.
59. Licinio, J., Yildiz, B., Wong, M.L., 2002. Depression and cardiovascular disease: cooccurrence or shared genetic substrates? Mol. Psychiatry 7, 1031-1032.
60. Maes, M., Ruckoanich, P., Chang, Y.S., Mahanonda, N., Berk, M., 2011. Multiple aberrations in shared inflammatory and oxidative&nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 769-783.
61. Matsuzaki, H., Tamatani, M., Yamaguchi, A., Namikawa, K., Kiyama, H., Vitek, M.P., Mitsuda, N., Tohyama, M., 2001. Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. 15, 1218-1220.
62. McCaffery, J.M., Frasure-Smith, N., Dubé, M.-P., Théroux, P., Rouleau, G.A., Duan, Q., Lespérance, F., 2006. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom. Med. 68, 187-200.
63. McCloskey, D.P., Croll, S.D., Scharfman, H.E., 2005. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J. Neurosci. 25, 8889-8897.
64. McEwen, B.S., 1998. Stress, adaptation, and disease. Allostasis and allostatic load. Ann. N. Y. Acad. Sci. 840, 33-44.
65. Meijer, A., Conradi, H.J., Bos, E.H., Thombs, B.D., van Melle, J.P., de Jonge, P., 2011. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen. Hosp. Psychiatry 33, 203-216.
66. Miller, A.H., Pariante, C.M., Pearce, B.D., 1999. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol. 461, 107-116.
67. Miller, G.E., Stetler, C.A., Carney, R.M., Freedland, K.E., Banks, W.A., 2002. Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 90, 1279-1283.
68. Miller, G.E., Freedland, K.E., Carney, R.M., 2005. Depressive symptoms and the regulation of proinflammatory cytokine expression in patients with coronary heart disease. J. Psychosom. Res. 59, 231-236.
69. Miller, G.E., Chen, E., Sze, J., Marin, T., Arevalo, J.M., Doll, R., Ma, R., Cole, S.W., 2008. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 64, 266-272.
70. Molloy, G.J., Perkins-Porras, L., Strike, P.C., Steptoe, A., 2008. Type-D personality and cortisol in survivors of acute coronary syndrome. Psychosom. Med. 70, 863-868.
71. Mondelli, V., Dazzan, P., Hepgul, N., di Forti, M., Aas, M., D'Albenzio, A., di Nicola, M., Fisher, H., Handley, R., Marques, T.R., Morgan, C., Navari, S., Taylor, H., Papadopoulos, A., Aitchison, K.J., Murray, R.M., Pariante, C.M., 2010. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 116, 234-242.
72. Morrison, M.F., Redei, E., Tenhave, T., Parmelee, P., Boyce, A.A., Sinha, P.S., Katz, I.R., 2000. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol. Psychiatry 47, 144-150.
73. Morrison, M.F., ten Have, T., Freeman, E.W., Sammel, M.D., Grisso, J.A., 2001. DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years. Biol. Psychiatry 50, 705-711.
74. Myint, A.M., Kim, Y.K., 2003. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61, 519-525.
75. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., 2007. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98, 143-151.
76. Myint, A.M., Schwarz, M.J., Muller, N., 2012. The role of the kynurenine metabolism in major depression. J. Neural Transm. 119, 245-251.
77. Niinisalo, P., Raitala, A., Pertovaara, M., Oja, S.S., Lehtimaki, T., Kahonen, M., Reunanen, A., Jula, A., Moilanen, L., Kesaniemi, Y.A., Nieminen, M.S., Hurme, M., 2008. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand. J. Clin. Lab. Invest. 68, 767-770.
78. Oades, R.D., Dauvermann, M.R., Schimmelmann, B.G., Schwarz, M.J., Myint, A.M., 2010. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication. Behav. Brain Funct. 6, 29.
79. Oldehinkel, A.J., van den Berg, M.D., Flentge, F., Bouhuys, A.L., ter Horst, G.J., Ormel, J., 2001. Urinary free cortisol excretion in elderly persons with minor and major depression. Psychiatry Res. 104, 39-47.
80. Otte, C., Marmar, C.R., Pipkin, S.S., Moos, R., Browner, W.S., Whooley, M.A., 2004. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: The Heart and Soul Study. Biol. Psychiatry 56, 241-247.
81. Ozkan, Y., Sukuroglu, M.K., Tulmac, M., Kisa, U., Simsek, B., 2014. Relation of kynurenine/tryptophan with immune and inflammatory markers in coronary artery disease. Clin. Lab. 3, 4.
82. Pace, T.W., Hu, F., Miller, A.H., 2007. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 21, 9-19.
83. Pariante, C.M., 2006. The glucocorticoid receptor: part of the solution or part of the problem? J. Psychopharmacol. 20, 79-84.
84. Pariante, C.M., Miller, A.H., 2001. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49, 391-404.
85. Parissis, J.T., Adamopoulos, S., Rigas, A., Kostakis, G., Karatzas, D., Venetsanou, K., Kremastinos, D.T., 2004. Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am. J. Cardiol. 94, 1326-1328.
86. Pedersen, E.R., Midttun, Ø., Ueland, P.M., Schartum-Hansen, H., Seifert, R., Igland, J., Nordrehaug, J.E., Ebbing, M., Svingen, G., Bleie, Ø., 2011. Systemic markers of interferon-c-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31, 698-704.
87. Penninx, B.W., Beekman, A.T., Bandinelli, S., Corsi, A.M., Bremmer, M., Hoogendijk, W.J., Guralnik, J.M., Ferrucci, L., 2007. Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamopituitary-adrenal axis. Am. J. Geriatr. Psychiatry 15, 522-529.
88. Pertovaara, M., Raitala, A., Juonala, M., Lehtimaki, T., Huhtala, H., Oja, S.S., Jokinen, E., Viikari, J.S., Raitakari, O.T., Hurme, M., 2007. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin. Exp. Immunol. 148, 106-111.
89. Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45.
90. Pizzi, C., Manzoli, L., Mancini, S., Costa, G.M., 2008. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur. Heart J. 29, 1110-1117.
91. Pruessner, J.C., Kirschbaum, C., Meinlschmid, G., Hellhammer, D.H., 2003. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28, 916-931.
92. Raison, C.L., Miller, A.H., 2003. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160, 1554-1565.
93. Ridker, P.M., 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-369.
94. Ridker, P.M., 2007. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129-2138.
95. Rohleder, N., Kudielka, B.M., Hellhammer, D.H., Wolf, J.M., Kirschbaum, C., 2002. Age and sex steroid-related changes in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. J. Neuroimmunol. 126, 69-77.
96. Rosti, V., Massa, M., Campanelli, R., de Amici, M., Piccolo, G., Perfetti, V., 2007. Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndrome. Haematologica 92, 1291-1292.
97. Sapolsky, R.M., Romero, L.M., Munck, A.U., 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21, 55-89.
98. Sarkar, S., Kalia, V., Montelaro, R.C., 2003. Caspase-mediated apoptosis and cell death of rhesus macaque CD4+ T-cells due to cryopreservation of peripheral blood mononuclear cells can be rescued by cytokine treatment after thawing. Cryobiology 47, 44-58.
99. Senger, D.R., Perruzzi, C.A., Feder, J., Dvorak, H.F., 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46, 5629-5632.
100. Shalev, H., Serlin, Y., Friedman, A., 2009. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc. Psychiatry Neurol. 2009, 278531.
101. Sondell, M., Lundborg, G., Kanje, M., 1999. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19, 5731-5740.
102. Stewart, J.C., Rand, K.L., Muldoon, M.F., Kamarck, T.W., 2009. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav. Immun. 23, 936-944.
103. Storkebaum, E., Lambrechts, D., Carmeliet, P., 2004. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26, 943-954.
104. Strickland, P.L., Deakin, J.F., Percival, C., Dixon, J., Gater, R.A., Goldberg, D.P., 2002. Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br. J. Psychiatry 180, 168-173.
105. Takebayashi, M., Hashimoto, R., Hisaoka, K., Tsuchioka, M., Kunugi, H., 2010. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J. Neural Transm. 117, 1119-1122.
106. Tylee, A., Ashworth, M., Barley, E., Brown, J., Chambers, J., Farmer, A., Fortune, Z., Haddad, M., Lawton, R., Mann, A., Mehay, A., McCrone, P., Murray, J., Leese, M., Pariante, C.M., Rose, D., Rowlands, G., Smith, A., Walters, P., 2011. Up-beat UK: a programme of research into the relationship between coronary heart disease and depression in primary care patients. BMC Fam. Pract. 12, 38.
107. Ventriglia, M., Zanardini, R., Pedrini, L., Placentino, A., Nielsen, M.G., Gennarelli, M., Bocchio-Chiavetto, L., 2009. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 146-149.
108. Walters, P., Barley, E.A., Mann, A., Phillips, R., Tylee, A., 2014. Depression in primary care patients with coronary heart disease: baseline findings from the UPBEAT UK study. PLoS ONE 9, e98342.
109. Warner-Schmidt, J.L., Duman, R.S., 2008. VEGF as a potential target for therapeutic intervention in depression. Curr. Opin. Pharmacol. 8, 14-19.
110. Webster, J.C., Oakley, R.H., Jewell, C.M., Cidlowski, J.A., 2001. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. USA 98, 6865-6870.
111. Whooley, M.A., Wong, J.M., 2013. Depression and cardiovascular disorders. Annu. Rev. Clin. Psychol. 9, 327-354.
112. Wichers, M., Maes, M., 2002. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5, 375-388.
113. Wichers, M.C., Maes, M., 2004. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatry Neurosci. 29, 11-17.
114. Wirleitner, B., Rudzite, V., Neurauter, G., Murr, C., Kalnins, U., Erglis, A., Trusinskis, K., Fuchs, D., 2003. Immune activation and degradation of tryptophan in coronary heart disease. Eur. J. Clin. Invest. 33, 550-554.
115. Yehuda, R., 2001. Biology of posttraumatic stress disorder. J. Clin. Psychiatry 62(Suppl. 17), 41-46.
116. Yoshimura, K., Yamada, M., Kajiwara, Y., Nishiguchi, S., Aoyama, T., 2013. Relationship between depression and risk of malnutrition among communitydwelling young-old and old-old elderly people. Aging Ment. Health 17, 456-460.